The Valley Desk

NCT04164901 · Interventional trial

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Overall registry status Active not recruiting

Phase 3

Conditions Grade 2 Glioma, Recurrent Glioma, Residual Glioma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov